Evidence map›Paper›PMID 37953402›Full record

ArticleAngewandte Chemie (International ed. in English)2024

Structural Basis of the Bivalency of the TRPV1 Agonist DkTx.

Venkatraman Ramanujam, Theo Crawford, Ben Cristofori-Armstrong, Jennifer R Deuis, Xinying Jia, Michael J Maxwell, Sina Jami, Linlin Ma, Irina Vetter, Mehdi Mobli

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Refining the NaFEBS letters · 2025
    Article
  3. Structural Basis of the Bivalency of the TRPV1 Agonist DkTx.Angewandte Chemie (International ed. in English) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Venkatraman RamanujamAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Theo CrawfordAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Ben Cristofori-ArmstrongAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Jennifer R DeuisInstitute for Molecular Biosciences, School of Pharmacy, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Xinying JiaAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Michael J MaxwellAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Sina JamiInstitute for Molecular Biosciences, School of Pharmacy, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Linlin MaGriffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Nathan, 4111, Queensland, Australia.
Irina VetterInstitute for Molecular Biosciences, School of Pharmacy, The University of Queensland, St Lucia, 4072, Queensland, Australia.
Mehdi MobliAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, 4072, Queensland, Australia.ORCID 0000-0003-2420-4262
The University of Queensland · AUGriffith University · AU

Funding

Australian Research Council DP190101177National Health and Medical Research Council APP1035102National Health and Medical Research Council APP1137011National Health and Medical Research Council APP1139961National Health and Medical Research Council APP1162427National Health and Medical Research Council APP1162503National Health and Medical Research Council APP1162597
6 · The paper itself

Abstract

Bivalency is a prevalent natural mechanism to enhance receptor avidity. Various two-domain disulfide-rich peptides exhibiting bivalent action have been identified from animal venoms. A unique characteristic of these peptides is that they induce a pharmacological response different from that provoked by any of the constituent domains. The enhanced potency and avidity of such peptides is therefore a consequence of their domain fusion by a peptide linker. The role of the linker itself, beyond conjugation, remains unclear. Here, we investigate how the linker affects the bivalency of the capsaicin receptor (TRPV1) agonist DkTx. We recombinantly produced isotope labelled DkTx using a protein splicing approach, to solve the high-resolution solution structure of DkTx, revealing residual linker order stabilised by linker-domain interactions leading to biased domain orientations. The significance of this was studied using a combination of mutagenesis, spin relaxation studies and electrophysiology measurements. Our results reveal that disrupting the pre-organisation of the domains of DkTx is accompanied by reductions in potency and onset of avidity. Our findings support a model of pre-configured two-domain binding, in favour of the previously suggested sequential binding model. This highlights the significance of ordered elements in linker design and the natural evolution of these in bivalent toxins.

Indexed as

Toxins, BiologicalAnimalsElectrophysiological PhenomenaPeptidesPeptidesToxins, BiologicalBivalentDisulfide-Rich PeptidesDkTxIntein-Mediated LigationNMR Spectroscopy

Identifiers

PMID37953402
PMCPMC10952689
OpenAlexW4388616104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.